Addiction of MYCN Amplified Tumours to B-MYB Underscores a Reciprocal Regulatory Loop by Gualdrini, Francesco et al.
www.impactjournals.com/oncotarget/  Oncotarget, August, Vol.1, No 4 
Oncotarget 2010; 1: 278-288 www.impactjournals.com/oncotarget 278
Addiction of MYCN Amplified Tumours to B-MYB Underscores a 
Reciprocal Regulatory Loop
Francesco Gualdrini1, Daisy Corvetta1, Sandra Cantilena1, Olesya Chayka1, Barbara 
Tanno2, Giuseppe Raschellà2 and Arturo Sala1
1 Molecular Haeamatology and Cancer Biology Unit, UCL Institute of Child Health, London WC1N 1EH, UK
2 ENEA Research Center, Laboratory of Radiation Biology and Biomedicine Via Anguillarese, 301, 00123 S. Maria di Galeria, 
Rome, Italy
Correspondence to:  Arturo Sala, e-mail: a.sala@ich.ucl.ac.uk
Keywords: neuroblastoma, oncogene, synthetic lethality, transcription factor
Received: May 19, 2010, Accepted: July 16, 2010, Published: August 4, 2010
Copyright: C 2010 Gualdrini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  
AbstrAct:
MYCN  is  a  member  of  the  MYC  family  of  oncoproteins  frequently  amplified  or 
overexpressed in aggressive, paediatric tumours of the nervous system.  In 
this  study  we  have  identified  the  gene  B-MYB, encoding  the  transcription  factor 
also known as MYBL2, as a downstream target of MYCN. Using multiple in silico 
databases  we  show  that  expression  of  B-MYB  significantly  correlates  with  that 
of  MYCN  in  neuroblastoma  patients.  MYCN  binds  to  and  activates  the  B-MYB 
gene  in vivo and in vitro.  Blunting  B-MYB  expression  by  RNA  interference 
causes  reduced  proliferation  of  MYCN  amplified,  but  not  MYCN-non  amplified, 
neuroblastoma cell lines, indicating that tumour cells are addicted to B-MYB in a 
MYCN dependent manner. Notably, B-MYB binds in vivo to the MYCN amplicon and 
is required for its expression. We conclude that MYCN and B-MYB are engaged in 
a reciprocal regulatory loop whose pharmacological targeting could be beneficial 
to  patients  with  the  aggressive  forms  of  cancer  in  which  MYCN  is  amplified. 
IntroductIon
Neuroblastoma is the most frequent extracranial 
solid cancer in childhood and is formed by proliferating 
precursor cells of the sympathetic nervous system that 
fail to terminally differentiate [1-3]. Neuroblastoma’s 
behaviour range from spontaneous regression to an infaust 
outcome [1].  In 1983 Schwab and colleagues identified a 
MYC-related oncogene, named MYCN, that was amplified 
in a panel of neuroblastoma cell lines [4].  Amplification 
of MYCN is detected in 20-30% of neuroblastomas and 
is the most important genetic aberration in this disease, 
strongly related to poor outcome [5]. MYCN is expressed 
in the migrating neural crest and encodes a protein with 
a basic helix-loop-helix [bHLH] domain that takes part 
in the Max network, with a crucial role in governing cell 
growth, apoptosis, and differentiation [6]. Transcription 
modulation of target genes is carried out by the hetero-
dimer Myc/Max which binds to the E-box consensus 
CA(C/T)GTG in target genes promoters with high 
efficiency [7]. Several studies established the strict link 
between  MYCN  amplification/over-expression  and  the 
transformed phenotype [8, 9], but it is still unclear what 
are the key cellular genes regulated by MYCN involved 
in its transforming ability. Furthermore, whether there are 
cellular factors limiting for the expression of the MYCN 
amplicon in neuroblastoma cells has not been investigated 
in previous studies. 
B-MYB is a transcription factor of the MYB family 
associated with advanced neuroblastoma stages and whose 
over-expression confers drug resistance to neuroblastoma 
cells [10, 11]. B-MYB is key for proliferation and survival 
of mammalian cells and embryonic development in mice 
[12]. B-MYB is thought to promote cell proliferation 
cooperating with factors important for the cell cycle, 
like E2Fs, or required for cell division, like cdc2, cyclin 
A2 and cyclin B1 [13-15]. Promotion of cell survival 
by B-MYB could be achieved by transactivation of pro-
survival genes such as BCL2 [16, 17]. Similar to other 
oncogenic transcription factors, B-MYB is broadly 
over-expressed or amplified in different types of human 
cancer including breast, lung, ovary carcinomas [18-22]. Oncotarget 2010; 1: 278-288 279 www.impactjournals.com/oncotarget
We have previously shown that B-MYB is associated to 
the risk of developing neuroblastoma, its expression is 
increased in patients with metastatic disease and predicts 
poor survival [11, 23]. 
In this study, we monitored the expression of 
B-MYB and MYCN in multiple microarray experiments 
containing data from hundreds of neuroblastoma patients. 
This analysis revealed that B-MYB is significantly co-
expressed with MYCN in neuroblastoma patients and 
in the follow-up experiments we show that MYCN and 
B-MYB regulate each other with important biological 
consequences. 
Figure 1: Expression of b-MYb correlates with MYcn status in neuroblastomas. A) Immunohistochemical analysis of 
B-MYB protein in primary human neuroblastomas. Strong nuclear B-MYB staining is detected in the MYCN amplified specimens [n=3]. B) B-
MYB gene expression profiling in 56 pretreatment primary neuroblastoma tumor samples. For each sample is specified the stage, the outcome 
(alive/dead) and the presence of MYCN amplification. Red indicates high whereas green indicates low gene expression levels. The expression 
profile was mined from the Oncogenomics web site (home.ccr.cancer.gov/oncology/oncogenomics/) C) Box plot of B-MYB mRNA epression in 
primary human neuroblastomas with or without MYCN amplification. The plot was obtained using the Oncomine Web site (www.oncomine.org), 
where the information regarding the neuroblastoma samples can also be found. Statistical significance was assessed by Student t test [p<0.001 in 
102 samples]. mRNA datasets are normalized by being log 2 - transformed, with the median set to 0 and SD set to 1. All statistical tests were two-
sided. C) Western blot analysis showing expression of B-MYB in MYCN amplified or non amplified cell lines. Antibodies recognising MYCN, 
B-MYB and actin [as a loading control] were used, as indicated. Oncotarget 2010; 1: 278-288 280 www.impactjournals.com/oncotarget
rEsults
b-MYb and MYcn are co-expressed in 
neuroblastoma tumours and cell lines
We assessed 24 primary neuroblastoma specimens 
by immunohistochemistry to study the expression 
and subcellular localisation of the B-MYB protein. 
Nuclear staining of B-MYB was frequently detected 
(54% of samples) in neuroblastomas and expression 
was particularly strong in MYCN amplified cases (Fig 
1A). To investigate whether the expression of B-MYB 
and  MYCN  is  statistically  significantly  correlated  in 
neuroblastoma patients, we have used three databases: 
Genesapiens    [24]  [www.genesapiens.org],  Oncomine 
[25] [www.oncomine.org] and Oncogenomics [26] [home.
ccr.cancer.gov/oncology/oncogenomics/].  We  firstly 
confirmed that the B-MYB mRNA is highly expressed 
in neuroblastoma tumours and its levels, in agreement 
with previous findings [11], correlate with poor patients’ 
survival (data not shomn). Interestingly, we observed that 
in all the available databases the expression of B-MYB 
is statistically significantly higher in specimens in which 
the MYCN proto-oncogene is amplified (Figure 1B,C and 
data not shown).
To verify the correlation between MYCN and 
B-MYB at the protein level, we carried out western blot 
analysis of B-MYB and MYCN expression in MYCN 
amplified  and  non  amplified  neuroblastoma  cell  lines. 
As expected, neuroblastoma cell lines with amplification 
of MYCN also over-express B-MYB, validating the 
microarray data (Fig 1D).
MYcn binds to and transactivates the b-MYb 
gene.
We sought to determine whether MYCN could 
directly regulate B-MYB. To verify the presence of MYC 
binding sequences in the B-MYB promoter, we used the 
TESS Web tool (www.cbil.upenn.edu/cgi-bin/tess/tess) 
[27]. There are 5 canonical and non canonical E-BOXes 
in the B-MYB promoter at position -1523 (CACCTG), 
-1427 (CACGTG), -840 (CACCGT), -415 (CACGTG), 
-319 (CAGGTG) (Figure 2A).
Analysis of the distribution of the MYC binding sites 
shows that each sequence is separated from one another 
by a distance in base pairs multiple of 140bp, necessary 
for a double turn of the DNA around the nucleosome.   
This means that all the E-BOXs are exposed on the same 
side of the DNA helix. Furthermore the distance between 
two  of  the  E-BOXes  (-1523/-1427  and  -415/-319)  is 
around 100bp. This distance is required for the formation 
Figure 2: MYcn binds to the b-MYb promoter in vivo and induces histones acetylation. A) distribution of the five 
putative E-BOXes on the B-MYB promoter found by the TESS analyzer tool [www.cbil.upenn.edu/cgi-bin/tess/tess]. B) Chromatin IP analysis 
of the MYCN protein bound onto the B-MYB promoter in SHSY5Y and SKNAS (non MYCN amplified) and LAN-1(MYCN amplified) neuro-
blastoma cell lines. Cross-linked chromatin was immuno-precipitated with MYCN or GAL4, used as a negative control, antibodies as indicated. 
C) Chromatin-IP analysis to assess the presence of acetylated histones H3 and H4 on the B-MYB promoter region containing the putative MYCN 
binding sites. The antibodies used are indicated on the top of the figure. D) Chromatin-IP analysis of factors bound onto the B-MYB promoter in 
the presence or absence of inducible MYCN. Antibodies used and conditions are shown in the top of the panel. Oncotarget 2010; 1: 278-288 281 www.impactjournals.com/oncotarget
of an anti-parallel tetramer between two MYCN-MAX 
heterodimers [28]. 
To verify that MYCN could interact with the B-MYB 
promoter  region  encompassing  the  putative  E-BOXes 
in human neuroblastoma cells in vivo, we carried out 
Chromatin-IP  analysis,  which  confirmed  that  MYCN 
binds to the B-MYB promoter only in a MYCN-amplified 
cell line (Figure 2B). This region of the B-MYB promoter 
bound by MYCN contains acetylated histones H3 and H4, 
suggesting that the chromatin is in a relaxed, active state 
(Figure 2C). 
To investigate whether histone acetylation was a 
direct effect of MYCN binding, we used a cell line which 
carry a MYCN cDNA under the control of a tetracycline-
inducible promoter. As expected, no binding of MYCN 
onto the B-MYB promoter was observed in uninduced 
cells, and acetylation of histones H3 and H4 was only 
observed after binding of MYCN on the promoter (Fig 
2D). 
To study the transcriptional regulation of B-MYB in 
human NB cells, we used a B-MYB promoter construct 
linked to the luciferase gene, containing the two E-BOXes 
most proximal to the transcription start site, including the 
canonical -415 E-BOX, or two additional constructs in 
which these E-BOXes are progressively deleted (Figure 
3A). MYCN over-expression caused a two fold increase 
in luciferase activity only in the presence of both the 
E-BOXes. Deletion of the distal, canonical -415 E-BOX 
sequence was sufficient to completely abrogate MYCN 
transactivation, suggesting that binding of MYCN to this 
promoter region is functionally relevant Figure 3B).
We next assessed whether MYCN could activate 
endogenous B-MYB in human cell lines. Firstly, 
MYCN was transiently transfected into H293 cells and 
Figure 3: MYcn transcriptionally activates b-MYb mrnA and protein. A) Schematic representation of three reporter 
vectors containing fragments of the B-MYB promoter: B-MYBp-pGL2 (from position -102 to -709, relative to the transcription start site); 5’-
Δ360 (from position -102 to position -360); 5’-Δ240 (from position -102 to -240). B) Quantifications of luciferase assays showing the activity 
of the B-MYB promoter segments in the presence or absence of exogenously expressed MYCN. Error bars indicate standard deviations and 
the asterisk indicates statistically significant differences [*=p<0.001] with respect to the levels of B-MYBp-pGL2 promoter activity, which was 
arbitrarily set to 1. C) Real time PCR analysis of B-MYB expression in 293 cells transiently transfected with a MYCN expression vector. The 
expression levels of four independent MYCN transfectants relative to cells transfected with empty vector are shown. Error bars indicate standard 
deviations obtained from triplicate assays. D) Western blot analysis showing enhanced expression of B-MYB caused by activation of MYCN in 
SKANAS::MYCN(ER) cells. (+ or -) 4-OHT indicates that the cells were cultured in the presence or absence of 4-hydroxytamoxifen, respectively. Oncotarget 2010; 1: 278-288 282 www.impactjournals.com/oncotarget
the  expression  of  the  B-MYB  mRNA  was  quantified 
by  Q-PCR. We  observed  a  1.56-  to  2.38-fold  increase 
in B-MYB expression levels after MYCN transfection 
(Figure 3C), Secondly, we used a neuroblastoma cell line 
containing a construct conditionally activating MYCN 
in the presence of 4-hydroxytamoxifen. After activation 
of MYCN, western blot analysis showed that B-MYB is 
induced at the protein level, validating the hypothesis that 
B-MYB is under the control of MYCN in human cancer 
cell lines (Figure 3D). 
b-MYb is essentially required for the proliferation 
of MYCN-amplified neuroblastoma cell lines
To determine whether expression of B-MYB 
is  required  for  proliferation  of  MYCN-amplified 
neuroblastoma  cells,  three  MYCN-amplified  (LAN-1, 
GI-LIN,  IMR-32)  and  two  MYCN  non  amplified  (GI-
MEN, ACN) cell lines were infected with lentiviruses 
carrying B-MYB, or scrambled shRNAs, and expressing 
GFP. After infections, cells were quickly selected with 
puromycin and GFP positive cells were counted and 
re-plated in 60mm dishes at low density. After 14 days, 
knock-down of B-MYB caused inhibition of proliferation 
of LAN-1, GI-LIN and IMR-32, but not GI-MEN and 
ACN, neuroblastoma cells (Figure 4A,B and C). The lack 
of  phenotypic  effect  in  the  non-MYCN  amplified  cell 
lines occurred despite the shRNA vector caused a marked 
downregulation of B-MYB protein expression (Figure 
S1). 
The  B-MYB  shRNA  caused  reduced  cell  cycle 
activity of LAN1 cells, which showed a block in G1, 
while  IMR-32  cells  were  not  affected  (Figure  S2), 
suggesting that the negative effect of B-MYB depletion 
on cell proliferation can be caused by reduced cell cycle 
activity or increased cell death. Indeed, we observed a 
marked increase of IMR-32 cells detaching from the dish 
during selection of cells infected with the B-MYB shRNA 
lentivirus, compared to the control virus-infected cells. 
These observations are in keeping with the hypothesis that 
B-MYB is downstream of MYCN since down-regulation 
Figure 4: B-MYB is required for proliferation of MYCN amplified cell lines. A) Proliferation assay of non MYCN ampli-
fied GIMEN and ACN cells infected with a lentiviruses expressing a scrambled or B-MYB shRNA, and selected with puromycin for 14 days. B) 
Proliferation assay of MYCN amplified GI-LIN, LAN-1 and IMR32 cells infected with lentiviruses expressing a scrambled or B-MYB shRNA, 
and selected with puromicin for 14 days. C) Quantification of the proliferation assays. The error bars indicate the standard deviations of the values 
obtained in 3 replicate infections. The experiment was repeated twice with similar results. Oncotarget 2010; 1: 278-288 283 www.impactjournals.com/oncotarget
of MYCN in neuroblastoma cells was previously shown 
to cause cell cycle arrest or apoptosis [29, 30]. 
b-MYb binds to and regulates the MYcn 
promoter
c-MYB and B-MYB regulate the expression of the 
prototype member of the MYC family, c-MYC [31]. We 
then speculated that B-MYB could be involved in the 
regulation of MYCN in the context of neuroblastoma. 
We firstly investigated whether MYB binding sites are 
present in the MYCN promoter. Analysis of about 2Kb 
of  the  5’  flanking  region  of  the  MYCN  gene  revealed 
that  there  are  7  putative  MYB  binding  sites. To  asses 
whether B-MYB binds the MYCN promoter in vivo, we 
performed Chromatin-IP assays on chromatin extracted 
from LAN-1 cells. We found that B-MYB is tightly 
bound to the MYCN promoter and the same chromatin 
domain contains acetylated histones, consistent with the 
idea that this segment of the MYCN promoter is active 
(Figure 5A). Next, we subcloned the MYCN promoter 
segment containing the MYB binding sites into the 
luciferase reporter vector PGL2 and investigated whether 
this was activated by B-MYB. We observed a weak but 
reproducible increase of MYCN promoter activity in 
the presence of exogenous B-MYB, suggesting that its 
interaction with the MYCN amplicon is functionally 
relevant (see discussion) (Figure 5B). 
To investigate whether a reciprocal feedback loop is 
operating in human neuroblastoma cells with amplification 
of MYCN, we infected IMR-32 cells with B-MYB, or 
scrambled, shRNA lentivirus. After puromicyn selection, 
the expression of B-MYB and MYCN was assessed by 
western blot analysis. We observed that knockdown of 
B-MYB affected the expression of MYCN and vice versa, 
suggesting that MYCN and B-MYB require each other 
for their expression (Figure 5C). Notably, the expression 
of c-MYB and the proliferation marker PCNA were 
unchanged by the knockdown of B-MYB or MYCN, 
demonstrating that their reciprocal regulation is specific 
and not a consequence of inhibition of cell proliferation. 
Figure 5: b-MYb binds to and regulates the MYcn promoter. A) Chromatin-IP analysis of proteins bound onto the MYCN 
promoter region encompassing the putative MYB-binding sites. Antibodies to immunoprecipitate B-MYB, acetylated histones H3 and H4 or 
GAL4 (used as a negative control) in LAN-1 [MYCN amplified] cells were used, as indicated in the top of the panel. B) Luciferase assay to assess 
MYCN promoter (MYCNp-pGL2) transcriptional activity in the presence or absence of exogenously expressed B-MYB. This assay was repeated 
several times until it reached statistical significance [*p<0.01] C] Western blot analysis of IMR32 cell lines infected with lentiviruses expressing, 
in order from left to right, sh::scrambled, sh::B-MYB and sh::MYCN, and selected with puromycin for 6 days. Whole cell lysates were prepared 
and subjected to western blot analysis with the indicated antibodies. Relative intensity of the bands are indicated on the top of the lanes. Oncotarget 2010; 1: 278-288 284 www.impactjournals.com/oncotarget
Exogenous overexpression of MYcn does not 
promote addiction to b-MYb in neuroblastoma 
cells
Addiction of MYCN amplified cell lines to B-MYB 
could be explained by two theories: a) B-MYB is required 
for expression of the MYCN amplicon and addiction of 
neuroblastoma cells to B-MYB reflects the dependence 
of amplified cell lines to MYCN expression; b) B-MYB 
is downstream of MYCN signalling and/or required to 
overcome senescence/apoptotic signals triggered by 
MYCN overexpression. 
To distinguish between these two possibilities, we 
stably transfected the non MYCN amplified cell line ACN 
with an expression vector containing the MYCN cDNA 
under the control of the CMV promoter. We then assessed 
whether ablating B-MYB expression by RNA interference 
caused a phenotypic effect in two independent MYCN 
expressing  clones.  As  opposed  to  naturally  amplified 
cell lines, the MYCN-transfected clones continued to 
proliferate normally in spite of reduced expression of 
B-MYB (Figure 6). Thus, we conclude that addiction 
of neuroblastoma cells to B-MYB is contingent on the 
presence of the MYCN amplicon and reflects the crucial 
role of B-MYB in its transcriptional regulation.
dIscussIon
Neuroblastoma is a challenging disease for 
clinicians, with an enigmatic and complex biology 
[1]. There are several cyctogenetic aberrations in 
neuroblastoma but, by far, the most clinically relevant 
is  the  amplification  of  MYCN.  MYCN  amplification 
is associated with metastatic disease and poor survival 
of neuroblastoma patients. Inhibition of MYCN by 
antisense or RNA interference approaches decreases the 
G1-S transition of the cell cycle or induces apoptosis in 
MYCN amplified neuroblastoma cells in culture [30, 32]. 
Furthermore, in the absence of  MYCN, NE2F and ID2 
expression is decreased whereas there is an increase of 
the growth suppressor p27 [29]. Transgenic expression 
of MYCN in the neuroectoderm causes neuroblastoma in 
mice, demonstrating its causative role in this disease [8]. 
In principle, MYCN could be an ideal target for therapy: 
it is aberrantly overexpressed in neuroblastoma and only 
marginally present in normal tissues. Apart from the 
intrinsic difficulty of targeting a transcription factor, the 
development of MYCN-targeting drugs is hampered by 
its extremely high expression in tumour cells. In principle, 
it would be better to direct clinical intervention towards 
genes upstream or downstream of the MYCN pathway, 
more amenable to drug inhibition. 
The product of the B-MYB [MYBL2] gene, is a 
transcription factor that modulates the cell cycle through 
activation of critical regulators of cell division, also 
required for cell survival. Aberrant B-MYB expression or 
amplification has been documented in different types of 
human cancers, suggesting a role in tumorigenesis [33-
35]. Furthermore B-MYB was recently implicated in 
Figure 6.  Exogenous expression of MYCN does not induce ad-
diction of neuroblastoma cells to B-MYB.  A) left panel: western 
blot analysis showing the expression of MYCN in ACN clones 
stably transfected with different dosages of the MYCN, or control, 
plasmids. Right panel: western blot analysis to detect the expres-
sion of B-MYB in the ACN/MYCN clones infected with B-MYB, 
or  scrambled  control,  shRNA  viruses.  B)  Proliferation  assay  of 
the MYCN, or control, ACN clones infected with the scrambled 
or B-MYB shRNA lentiviruses. Quantification of the percentages 
of GFP positive (infected) cells at the indicated days shows that 
proliferation of the different cell lines is not affected by depletion 
of B-MYB. Please note that in this assay cells were not counted 
and plated equally at the start of the experiment and the different 
percentages of GFP positivity at time 0 reflect variable infection 
efficiency. Oncotarget 2010; 1: 278-288 285 www.impactjournals.com/oncotarget
the maintenance of pluripotency, chromatin stability and 
normal cell cycle progression [36-38]. 
There is some evidence that B-MYB might have 
a role in neuroblastoma. For example, we have shown 
previously  that  the  expression  of  B-MYB  stratifies 
patients with aggressive forms of the disease and specific 
variants of B-MYB are associated with an increased 
risk of developing neuroblastoma [11, 23]. Furthermore, 
B-MYB is aberrantly stabilised in neuroblastoma cell 
lines, increasing its pro-survival function [39].  The Ishii 
laboratory was the first to show a relationship between 
MYC and MYB transcription factors by reporting that 
c-MYB and B-MYB are able to bind to and transactivate 
c-MYC promoter segments in gel shifts and transient 
transfection assays, respectively [31]. In the light of 
this study, we asked whether MYCN and B-MYB were 
functionally linked in neuroblastoma and, if so, what are 
the functional consequences. We initially observed that 
MYCN and B-MYB are co-expressed in neuroblastoma 
patients with aggressive or fatal disease (Figure 1A). 
We then went on to show that B-MYB expression is 
selectively required for proliferation of MYCN amplified 
tumours unveiling a reciprocal regulatory loop of the two 
transcription factors in neuroblastoma. 
A number of findings described in this study have 
important  biological  and  clinical  significance.  Firstly, 
B-MYB depletion causes synthetic lethality in MYCN 
amplified  cell  lines,  demonstrating  its  key  role  in  the 
regulation of the MYCN amplicon. B-MYB is a relatively 
weak, ubiquitous transcription factor and we speculate 
that in normal physiological settings it is not essential 
for the transcription of MYCN, whose expression 
is  strictly  tissue  specific.  On  the  other  hand,  MYCN 
could be involved in the expression of B-MYB during 
neurogenesis. Indeed, B-MYB is expressed under the 
control of neuronal signalling molecules like MELK and 
it is required for proliferation and survival of progenitor 
cells in the developing nervous system [40].  One likely 
scenario is that in tumours of the nervous system like 
neuroblastoma, the generation of multiple copies of 
the MYCN gene in DM bodies or HSRs chromosomes 
causes accumulation of the MYCN oncoprotein which 
binds to the B-MYB locus, activating its unregulated 
expression. This, in turn, will initiate a pathological 
regulatory cycle where B-MYB, in spite of its intrinsically 
weak transcriptional activity (Figure 5B), will cause a 
significant enhancement of MYCN expression due to the 
large number of amplicons available (see model in Figure 
7). This theory should explain the apparent paradox of 
a ubiquitous factor -B-MYB- being upstream of a tissue 
specific factor –MYCN- and clarify why MYCN is not 
activated in the vast cohort of non-neuronal tumours 
where B-MYB is overexpressed or amplified. 
Our work has potential clinical implications. Given 
their  reliance  on  B-MYB,  tumours  with  amplification 
of MYCN should be exquisitely sensitive to its 
pharmacological targeting, indicating that the search for 
small molecule inhibitors of B-MYB is warranted. 
MAtErIAls And MEthod
Patient samples and immunohistochemistry
The use of tumour samples was authorized by the 
National Research Ethics Service (NRES), REC reference 
number 10/H0706/19. Patient archival diagnostic samples 
were identified by searching the histopathology database 
of a single institution (Great Ormond Street Hospital) using 
the search criteria neuroblastoma or ganglioneuroblastoma 
and identifying cases diagnosed between August 1994 and 
August 2005. Amplification of MYCN was identified by 
real time PCR. 
Sections  (4mm)  from  formalin-fixed  paraffin 
embedded samples (24 patients) were cut and mounted 
onto slides, which were treated with xylene and graded 
alcohol, and equilibrated in PBS. Antigen retrieval was 
performed by microwaving for 5 min (three times at 
400W) in a buffer containing 10mM sodium citrate pH 6. 
Of the 24 patients analysed, 13 were positive for nuclear 
B-MYB (54%). Among the positives samples, 3 were 
MYCN amplified. None of the B-MYB negative samples 
were MYCN amplified. 
Figure 7. Schematic representation of the feedback loop govern-
ing B-MYB and MYCN expression in MYCN amplified cell lines.Oncotarget 2010; 1: 278-288 286 www.impactjournals.com/oncotarget
Antibodies
Monoclonal anti-B-MYB [41], was kindly provided 
by Roger Watson. Other primary antibodies used were: 
anti-MYCN,  anti-B-MYB,  anti-Actin  (Santa  Cruz 
Biotechnology), anti-acethyl histone H3 and H4 (Upstate). 
Horseradish peroxidase-conjugated secondary antibodies 
were purchased from GE Healthcare Life Sciences. 
Plasmids
652 base pairs of the MYCN promoter (from position 
-32 to -684) were cloned into the pGL2-basic vector 
(Promega) and were obtained by amplifying this region 
from human genomic DNA using the following primers: 
FW-5’AACTCGAGGAGGGGAAGGATTTGTG  3’  
Rev- 5’ATTAAGCTTCTTTCCGCCCCGTTCG 3’.  The 
PCR product was cloned into the topo-vector (Invitrogen) 
and sub-cloned again into the pgl2-basic (Promega) using 
XhoI and HindIII restriction sites. The pGL2 constructs 
containing segments of the B-MYB promoter were 
described previously [42]. CMV-BMYB and CMV-
MYCN we also described in previous studies [23, 43]. 
Trans-Lentiviral™ GIPZ vectors coding for three types 
of shRNA::B-MYB (V2LHS_152045, V2LHS_152043, 
V2LHS_263085),  three  for  MYCN  (V2LHS_4509, 
V2LHS_36751,  V2LHS_36755)  and  one  scrambled 
pGIPZ (RHS_4346) were from Open Biosystem.
cell lines.
LAN-1,  IMR-32  and  HEK293T  cell  lines  were 
obtained from ATCC and maintained in DMEM media 
(Invitrogen) supplemented with 10% FBS (Invitrogen), 
penicillin, streptomycin, sodium pyruvate and non 
essential amino acid. ACN, GI-LIN, GI-MEN were a kind 
gift of Mirco Ponzoni (Gaslini Hospital, Genova, Italy), 
SK-NAS::MYCN[ER] cell lines were a gift from Mike 
Hogarty (University of Pennsylvania, Philadelphia, USA) 
and SHSY-5Y cells conditionally expressing MYCN under 
the control of a tetracycline responsive promoter were a 
gift from Giovanni Perini (University of Bologna, Italy). 
Neuroblastoma cell lines were authenticated by assessing 
the expression of MYCN and the neuronal marker CD56. 
transfections and luciferase report Assay
Transfections were carried out with Lipofectamine 
2000 following the manufacturer’s protocol (Invitrogen). 
Luciferase activity was assessed with the luciferase Assay 
Kit (Promega).
real-time Pcr
Quantitative  real-time  PCR  was  carried  out  with 
the Taq-man Master Mix (Applied Biosystems) using the 
ABI-PRISM 7000 Sequence Detection System. Primers 
and probes were purchased from Applied Biosystems. The 
expression of each gene was normalized using GADPH 
as  a  reference,  and  relative  levels  were  quantified  by 
calculating 2−ΔΔCt, where the ΔΔCt is the difference in 
Ct between target and reference.
Western blot Analysis
Cells were lysates in RIPA Buffer (10 mM Tris-Cl 
[pH 8.0], 1 mM EDTA, 1% Triton X-100, 0.1% sodium 
deoxycholate, 0.1% SDS, 140 mM NaCl) and protease 
inhibitors (Roche). Proteins were separated by SDS/PAGE 
on  10%  gels,  transferred  to  poly  vinylidene  difluoride 
membrane (Amersham Pharmacia), and incubated with 
antibodies.  Immunoblots  were  visualized  by  using  the 
enhanced chemiluminescent system (Thermo). 
chromatin immunoprecipitation (chIP) and gel 
shift
For  ChIP  assays,  after  fixing  the  protein/DNA 
complexes with formaldehyde we prepared lysates from 1.0 
× 107  log-phase neuroblastoma cells essentially as described 
by the manufacturer’s protocol (ActiveMotif’s ChIP-IT 
Express kit). Immunoprecipitated chromatin was amplified 
using the following primers pairs: B-MYB promoter, 
forward,  5′-GGACCCAGTAGTGGCTTGGA-3′; 
reverse,  5′-CGCTACTTCGGAGTTGTGGA-3′.  MYCN 
promoter: forward, 5′-CCCTGCTATCATTTGCACTC-3′; 
reverse  5′-CGTTTTAATACCGGGGGTGC-3’. 
Gel shift analysis was carried out as described 
previously [10]. The oligonucleotides used to 
generate the double straneded probes were:   
Wild type E-box:     
5’-CCCGGACTGACACGTGAGCCAGGCCTCG-3’   
Mutant E-box:   
5’ CCCGGACTGATACCTGAGCCAGGCCTCG 3’
lentiviral constructs and infections
For lentiviral shRNA expression, viral particles were 
produced in HEK-293T cells transfected with appropriate 
packaging plasmids. pGIPZ lentiviral vector was obtained 
from Open Biosystems, Surrey, UK. The non-silencing 
shRNAmir construct (scrambled shRNA) served as the 
negative control. 24 hrs after transfections, supernatants 
were collected, supplemented with 8 mg/ml of polybrene 
(Sigma) and filtered through a 0.45-mm filter unit. Target Oncotarget 2010; 1: 278-288 287 www.impactjournals.com/oncotarget
cells were infected for 24-h at 37 °C. To asses the effect 
of shRNA lentiviruses on cell proliferation, cells were and 
rapidly selected with puromycin (1-5 μg/ml) for 3-4 days. 
GFP positive cells (0.3x10^6 cell in 60mm dish) were 
plated and counted after 14 days. 
cell cycle analysis
Cells  were  fixed  on  ice  with  70%  ethanol,  then 
washed and resuspended in PBS containing 2mg/ml 
Propidium Iodide, 0.1% NP-40 and RNAse followed by 
FACS analysis. 
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